ewsba.se
Strong first-quarter performance was primarily driven by pricing growth of 4%, which successfully outpaced a modest decline in same-unit volumes across service lines.
Pricing strength was supported by four key factors: robust revenue cycle management (RCM) cash collections, increased contract administrative fees, favorable payer mix, and higher patient acuity in neonatology.
Management noted that while major hospital systems have reported revenue declines due to tax subsidy lapses, Pediatrix has not yet seen a corresponding headwind in its payer mix.
The company is doubling down on clinical quality as a competitive moat, hiring top academic physician leaders to drive data-based care variation reduction and improve patient outcomes.
Operational strategy is shifting toward leveraging the company's leading hospital footprint to expand teleservices and obstetrics presence nationwide.
The 'Pediatrix Partners' program was launched to align clinician compensation with share price performance, fostering a spirit of ownership among 45 inaugural physician leaders.
Management reaffirmed the full-year 2026 adjusted EBITDA guidance of $280 million to $300 million, assuming fairly ratable performance over the remaining three quarters.
The company maintains a flat pricing outlook for the full year, anticipating that the significant RCM cash collection benefits seen in Q1 will tail off as the year progresses.
Guidance does not currently include a headwind estimate for potential tax subsidy lapses, as management has not yet observed data supporting a negative trend in their specific business lines.
Future growth is expected to be supported by a strong balance sheet, with plans to deploy capital toward acquisitions that expand core and emerging service areas.
The company will initiate a search for a new General Counsel following the announced retirement of Mary Ann Moore, who serves as both General Counsel and Chief Information Officer, later this year.
Practice-level salary, wages, and benefits increased by $9 million, reflecting a 3% average increase in clinical salary expense consistent with the past 18 months.
Accounts receivable DSO improved by over five days year-over-year, reaching 42.5 days due to enhanced collection efforts at existing units.
The company utilized $21 million in capital to repurchase 1 million shares during the first quarter, ending with a net leverage ratio of approximately 1.3 times.
Portfolio restructuring efforts resulted in some revenue decreases, which were partially offset by $6 million in growth from recent acquisitions and organic activity.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management expects pricing to tick down as RCM cash collection benefits, which accounted for 25% of the pricing increase, begin to lap in the second half of the year.
Contract administrative fees contributed approximately 20% of the pricing growth, though management noted these negotiations with hospitals are becoming increasingly difficult.
While NICU days were down 1% in Q1, management stated that recent results do not show a continuation of a downward trend.
The company is not adjusting its volume forecast, as they do not see a definitive trend established by the recent modest declines.
Management has not seen any signs of weakness in payer mix across any geography or service line despite broader industry concerns.
They speculated that patients may be prioritizing exchange coverage for pregnancy-related care, though they remain cautious about potential delayed effects.
Recent acquisitions are currently performing better than initial internal projections.
The company is actively pursuing new opportunities that align with its core neonatology and maternal-fetal medicine footprint.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.